Analyst Ross Osborn works at CANTOR FITZGERALD and is covering the the Healthcare sector with 12 price targets and ratings documented since 2022 spanning on 3 stocks.
Ross Osborn's average stock forecast success ratio is 50% with an average time for price targets to be met of 25.33 days.
Most recent stock forecast was given on SIBN, SI-BONE, Inc at 28-Feb-2023.
Analyst best performing recommendations are on SIBN (SI-BONE, INC).
The best stock recommendation documented was for PACB (PACIFIC BIOSCIENCES OF CALIFORNIA, INC) at 1/20/2023. The price target of $12 was fulfilled within 13 days with a profit of $0.71 (6.29%) receiving and performance score of 4.84.
Average potential price target upside
Currently, out of the existing stock ratings of Ross Osborn - 7 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
17
$3.22 (23.37%)
14
5 days ago
5/11 (45.45%)
$9.28 (66.39%)
64
Buy
12
$-1.78 (-12.92%)
19
4 months 21 days ago
1/2 (50%)
$6.65 (101.12%)
13
Buy
12
$-1.78 (-12.92%)
5 months 5 days ago
1/1 (100%)
$3.47 (40.68%)
12
Hold
6
$-7.78 (-56.46%)
6
9 months 22 days ago
3/4 (75%)
$1.04 (7.22%)
154
Hold
14
$0.22 (1.60%)
41
1 years 1 months 4 days ago
3/5 (60%)
$2.25 (29.16%)
149
